This page shows the latest Exondys 51 news and features for those working in and with pharma, biotech and healthcare.
that the firm was emboldened by the FDA’s approval last year of another DMD therapy from Sarepta - Exondys 51 (eteplirsen) - after Janet Woodcock, head of the agency’s Center for
The exon-skipping drug raised functional dystrophin levels. Sarepta is preparing to file a follow-up to its Duchenne muscular dystrophy (DMD) treatment Exondys 51 that seems to have greater efficacy. ... normal from an average baseline level of 0.095% of
The agency granted orphan and priority review status for the drug, which is the second DMD treatment to be approved in the US after Sarepta Therapeutics' exon-skipping therapy Exondys 51 ... Marathon's chief executive Timothy Cunniff, alluding to the
Last month the FDA approved Sarepta's Duchenne muscular dystrophy (DMD) drug known as Exondys 51. ... Remember that some members of the FDA committee reviewing the data on Exondys 51 thought the drug should be approved.
Sarepta shares closed up 74% yesterday after news of the conditional approval for Exondys 51 (eteplirsen) broke - taking investors by surprise. ... Exondys 51 is indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon
More from news
Approximately 3 fully matching, plus 2 partially matching documents found.
Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US
Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...